Patents Examined by Kathleen K. Fonda
  • Patent number: 6852708
    Abstract: For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of a form of Hyaluronic Acid selected from Hyaluronic Acid, salts thereof and combinations thereof to the animal to prevent narrowing of the tubular walls.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: February 8, 2005
    Assignee: Jagotec AG
    Inventors: Rudolf Edgar Falk, Samuel Simon Ascuali, Eva Anne Turley
  • Patent number: 6838448
    Abstract: A solution for storing corneal tissue, especially at a temperature of 2 to 8° C., which comprises hyaluronic acid having an average molecular weight of less than 6,000,000 Da (preferably of from 50,000 to 250,000 Da).
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: January 4, 2005
    Inventor: Diego Ponzin
  • Patent number: 6770672
    Abstract: The present invention provides an antiproliferative compound having the structural formula wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: August 3, 2004
    Assignee: Research Development Foundation
    Inventors: Bob G. Sanders, Kimberly Kline, Laurence Hurley, Robb Gardner, Marla Menchaca, Weiping Yu, Puthucode N. Ramanan, Shenquan Liu, Karen Israel
  • Patent number: 6756208
    Abstract: The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: June 29, 2004
    Inventors: John H. Griffin, Hiroshi Deguchi, Jose Fernandez
  • Patent number: 6743783
    Abstract: The present invention relates to a purified, easily produced poly-&bgr;-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a &bgr;-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: June 1, 2004
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
  • Patent number: 6703377
    Abstract: A bone growth-promoting composition is provided comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at an intra-articular site of desired bone growth for a period of time sufficient to promote the bone growth. Preferably hyaluronic acid is used in a composition range of 0.1-4% by weight and preferred growth factor is bFGF, present in a concentration range of about 10−6 to 100 mg/ml.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: March 9, 2004
    Assignee: DePuy Acromed, Inc.
    Inventor: Michael Radomsky
  • Patent number: 6689763
    Abstract: This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-B1, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism Streptomyces spp. LL-AA896 which are useful an anti-bacterial agents.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: February 10, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Guy Thomas Carter, Jason Arnold Lotvin, Leonard Alexander McDonald
  • Patent number: 6686342
    Abstract: The present invention relates to a purified, easily produced poly-&bgr;-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a &bgr;-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 3, 2004
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
  • Patent number: 6683056
    Abstract: wherein when Y is  or heteroaryl; A is —O(CH2)m, S, —NH(CH2)m, or (CH2)n where n is 0-3 and m is 0-2; and R1 to R6 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents, and/or one, two or more hypolipidemic agents.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: January 27, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: William N. Washburn, Philip M. Sher, Gang Wu
  • Patent number: 6683064
    Abstract: A carrier and a method for preparing it are provided for use in the delivery of therapeutic agents. A polysaccharide is reacted with an oxidizing agent to open sugar rings on the polysaccharide to form aldehyde groups. The aldehyde groups are reacted to form covalent oxime linkages with a second polysaccharide and each of the first and second polysaccharide is selected from the group consisting of hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan, heparan sulfate and alginate.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: January 27, 2004
    Assignee: DePuy Acromed, Inc.
    Inventors: Andrea Y. Thompson, Lin Shu Liu, Robert C. Spiro
  • Patent number: 6680340
    Abstract: This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: January 20, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Kang Cheng, Samuel D. Wright, Tsuei-Ju Wu
  • Patent number: 6680306
    Abstract: The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: January 20, 2004
    Assignee: GlycoGenesys, Inc.
    Inventors: Yan Chang, Vodek Sasak
  • Patent number: 6680339
    Abstract: 15-fluoro substituted analogs of PGF2&agr; and methods of their use in treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 20, 2004
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Peter G. Klimko, Mark R. Hellberg, Paul W. Zinke
  • Patent number: 6670340
    Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p—; o and p are independently 0-4; X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl; R1 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: December 30, 2003
    Assignee: Akzo Nobel
    Inventors: Mingiang Zhang, Ronald Palin, David Jonathan Bennett
  • Patent number: 6667296
    Abstract: A method for preventing, reducing or treating radiation cystitis caused by external beam radiation therapy, which impinges on the urinary bladder and associated structures, comprising administering into the urinary bladder and associated structures a composition comprising hyaluronic acid (HA) having an average molecular weight of not less than 2×105 Daltons and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: December 23, 2003
    Inventor: Peter J. Pommerville
  • Patent number: 6664243
    Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1-R13 are as defined herein.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: December 16, 2003
    Assignee: Wyeth
    Inventor: Scott C. Mayer
  • Patent number: 6656923
    Abstract: The present invention relates to a stable, aqueous odor-absorbing and wrinkle controlling composition, preferably for use on inanimate surfaces, especially fabrics. The composition comprises from about 0.1% to about 20%, by weight of the composition, of solubilized, water-soluble, uncomplexed cyclodextrin and an effective amount of at least one ingredient to improve the performance of the composition selected from the group consisting of: (1) cyclodextrin compatible surfactant; (2) cyclodextrin compatible antimicrobial active; and (3) mixtures thereof. The composition also comprises a wrinkle control agent which is fabric lubricant, shape retention polymer, hydrophilic plasticizer, lithium salt, or mixtures thereof. Hydrophilic perfume improves acceptance. Optionally, the composition can contain low molecular weight polyols; metallic salts to help control odor; a humectant, etc. The composition is essentially free of any material that would soil or stain fabric.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: December 2, 2003
    Assignee: The Procter & Gamble Company
    Inventors: Toan Trinh, Raymond Edward Bolich, Jr., Helen Bernardo Tordil, Robert Mermelstein, Marjorie Mossman Peffly, Ricky Ah-Man Woo, Daniel Scott Cobb, Eva Schneiderman, Ann Margaret Wolff, Erin Lynn Rosenbalm, Thomas Edward Ward, Alex Haejoon Chung, Anthony James Burns, William Tucker Campbell, Alen David Streutker
  • Patent number: 6653456
    Abstract: A method of making a derivatized aminoglycoside includes reacting an aminoglycoside with at least 2 equivalents of a divalent metal ion in an aprotic solvent to complex two neighboring amino group and hydroxyl group pairs; reacting the non-complexed amino groups with a protecting reagent to provide protecting groups; removing the divalent metal ion to provide two unprotected amino groups; reacting one of the unprotected amino groups with a reactive substance containing an linker, a carrier, or a label; and removing the protecting groups. This method can be used to produce novel compounds and reagents.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: November 25, 2003
    Assignee: Roche Diagnostics Corporation
    Inventors: Mitali Ghoshal, Salvatore J. Salamone
  • Patent number: 6653294
    Abstract: The invention relates to a method of reducing nitric oxide production by a cell in vitro or in a mammal by a cell by contacting the cell with chitosan or its derivatives in an amount effective to reduce nitric oxide production in the cell.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: November 25, 2003
    Assignee: Food Industry Research & Development Institute
    Inventors: Shiaw-Min Hwang, Chiung-Yun Chen, Shan-Shan Chen, Jian-Chyi Chen
  • Patent number: RE38520
    Abstract: A subject of the invention is the compounds of formula (I): in which: X represents a CH2 or SO2 radical or an oxygen atom, Y represents a (CH2)m—(CH═CH)n(CH2)o radical, with m+n+o≦8, n=0 or 1, Ar represents an aryl radical, W represents a hydrogen atom, or the remainder of a carbamate function. The compounds of formula (I) have useful antibiotic properties.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: May 18, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Constantin Agouridas, Jean-Francois Chantot